I. Taguchi
I. Taguchi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
A. Oku
Discovery Research Laboratory, Tanabe Seiyaku Co. Ltd., 2-2-50 Kawagishi, Toda, Saitama 335-8505, Japan
1 shared publicationK. Kitamura
Discovery Research Laboratory, Tanabe Seiyaku Co. Ltd., 2-2-50 Kawagishi, Toda, Saitama 335-8505, Japan
1 shared publicationK. Oka
Discovery Research Laboratory, Tanabe Seiyaku Co. Ltd., 2-2-50 Kawagishi, Toda, Saitama 335-8505, Japan
1 shared publicationM. Matsumoto
Discovery Research Laboratory, Tanabe Seiyaku Co. Ltd., 2-2-50 Kawagishi, Toda, Saitama 335-8505, Japan
1 shared publicationM. Sugiura
Discovery Research Laboratory, Tanabe Seiyaku Co. Ltd., 3-16-89 Kashima, Yodogawa-ku, Osaka 532-8505, Japan, Fax +81 663 002593
1 shared publication
Latest Publications
- 1 July 1999
- Published by Springer Nature in Inflammation Research
- Vol. 48 (7) , 380-385
Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis
Objective and Design: To study the effect of cellular cAMP-increasing agents on Propionibacterium acnes (P. acnes) and lipopolysaccharide (LPS)-induced mouse hepatitis.¶Material: Male BALB/c mice were used. Macrophages/Kupffer cells isolated from P. acnes-primed murine liver were used for the in vitro study.¶Treatment: Type IV phosphodiesterase (PDE)-specific inhibitor, rolipram, was administered (10, 30 mg/kg, p.o.). Dibutyryl cyclic AMP (dbcAMP) was injected (10, 100 mg/kg, i.p.) into the mice.¶Method: Plasma TNFα estimated by the use of an L-929 cell cytotoxic assay and plasma transaminase activities were measured for the in vivo study. The LPS-induced production of TNFα in vitro from the cultured macrophage/Kupffer cells was determined by ELISA.¶Results: Rolipram suppressed the elevation of plasma transaminases induced by injection of LPS, and dbcAMP had a tendency to suppress them. Both agents attenuated the LPS-induced release of TNFα in vivo, and suppressed the TNFα production from the cultured macrophage/Kupffer cells.¶Conclusions: These results suggest that rolipram and dbcAMP have potential to inhibit TNFa production from activated macrophage/Kupffer cells, and it may be partially involved in the protecting effect in the P. acnes/LPS hepatitis model.
- 1 July 1999
- Published by Springer Nature in Inflammation Research
- Vol. 48 (7) , 380-385
Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis
Objective and Design: To study the effect of cellular cAMP-increasing agents on Propionibacterium acnes (P. acnes) and lipopolysaccharide (LPS)-induced mouse hepatitis.¶Material: Male BALB/c mice were used. Macrophages/Kupffer cells isolated from P. acnes-primed murine liver were used for the in vitro study.¶Treatment: Type IV phosphodiesterase (PDE)-specific inhibitor, rolipram, was administered (10, 30 mg/kg, p.o.). Dibutyryl cyclic AMP (dbcAMP) was injected (10, 100 mg/kg, i.p.) into the mice.¶Method: Plasma TNFα estimated by the use of an L-929 cell cytotoxic assay and plasma transaminase activities were measured for the in vivo study. The LPS-induced production of TNFα in vitro from the cultured macrophage/Kupffer cells was determined by ELISA.¶Results: Rolipram suppressed the elevation of plasma transaminases induced by injection of LPS, and dbcAMP had a tendency to suppress them. Both agents attenuated the LPS-induced release of TNFα in vivo, and suppressed the TNFα production from the cultured macrophage/Kupffer cells.¶Conclusions: These results suggest that rolipram and dbcAMP have potential to inhibit TNFa production from activated macrophage/Kupffer cells, and it may be partially involved in the protecting effect in the P. acnes/LPS hepatitis model.